From: Inside Precision Medicine <GEN@mail.insideprecisionmedicine.com>
Date: July 19, 2024 at 12:15:22 PM GMT-3
To: mxh5000@gmail.com
Subject: Switching Off Inflammatory Protein IL-11 Extends Lifespan and Reduces Age-Related Diseases in Mice
Reply-To: Inside Precision Medicine <update@clinicalomicsmail.com>

Inhibiting IL-11 extends lifespan offering potential anti-aging therapies.

Reference

View email in a browser | Forward to a Colleague

Inside Precision Medicine

Inside Precision MedicineTODAY July 19, 2024 Switching Off Inflammatory Protein IL-11 Extends Lifespan and Reduces Age-Related Diseases in Mice In a new study, scientists at the Medical Research Council Laboratory of Medical Sciences and Imperial College London have discovered that "switching off" a protein called IL-11 can significantly extend the healthy lifespan of mice by nearly 25 percent. + MORE AI-Human Interaction Could Aid Pancreatic Cancer Diagnosis Artificial intelligence could help distinguish cancerous and non-cancerous lesions in the pancreas and may be particularly helpful for novice endoscopists, trial findings suggest. + MORE Roche Oral GLP-1 Agonist Scores in Early Trial Roche has announced positive interim results from an ongoing Phase I trial for its oral small molecule GLP-1 receptor agonist which would enter a highly competitive market. + MORE Million Veteran Program Bridges Diversity Gap in Genome-Wide Association Studies Researchers have now published the results of a GWAS using samples from the United States Department of Veterans Affairs (VA) Million Veteran Program (MVP) that includes more than 635,000 samples--29 percent of them from individuals of color, i.e. those who do not self-identify as non-Hispanic White. + MORE SPONSORED Companion Diagnostics (CDx)--A Central Laboratory Perspective Strong technical, regulatory, and operational delivery capabilities required for CDx development. + MORE DIGITAL EXCLUSIVE: Building a Bridge Between Rare Disease Patients and the Technologies that Could Help Them Julia Vitarello is on a personal mission to open up access to individualized therapies for people with rare diseases, starting in the U.K. with the government-backed Rare Therapies Launch Pad. + MORE About Precision Medicine Subscribe Advertising Stay Connected: Inside Precision Medicine Mary Ann Liebert, Inc., publishers 140 Huguenot Street, New Rochelle, NY 10801, USA MANAGE e-SUBSCRIPTIONS Update All Email Preferences | View IPM Privacy Policy You have received this email at mxh5000@gmail.com. Unsubscribe